For nearly 50 years, Genentech has pursued groundbreaking science to discover and develop innovative medicines for people facing serious and life-threatening diseases.
Genentech pioneered the biotech industry and revolutionized how we treat some of the world’s most complex health problems, as a member of the Roche Group.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Lonza Group AG is a Swiss multinational manufacturing company based in Basel, specializing in contract development and manufacturing services for the pharmaceutical, biotechnology, and nutrition sectors. Founded in 1897, Lonza has evolved from its origins in hydroelectric power to become a leader in biopharmaceutical manufacturing, operating over thirty development and manufacturing sites worldwide.
As a pure-play contract development and manufacturing organization (CDMO), Lonza offers a wide range of services, including biologics manufacturing, small molecules production, bioconjugates, and cell and gene therapies. The company also provides drug product services and detection systems for the bioscience sector. Lonza has established significant partnerships with major pharmaceutical companies, including a notable collaboration with Moderna for the production of its COVID-19 vaccine. With a strong market position, Lonza plays a crucial role in the growth of outsourced drug manufacturing and the development of innovative therapies.